Kalaria R N, Andorn A C, Tabaton M, Whitehouse P J, Harik S I, Unnerstall J R
Department of Neurology, University Hospitals of Cleveland, OH 44106.
J Neurochem. 1989 Dec;53(6):1772-81. doi: 10.1111/j.1471-4159.1989.tb09242.x.
Loss of pigmented noradrenergic locus ceruleus neurons occurs in Alzheimer's disease (AD) and, to a lesser extent, in aging. We studied beta-adrenergic receptors and their subtypes, beta 1 and beta 2, by the specific binding of 125I-pindolol to particulate membrane preparations from prefrontal cortex, hippocampus, putamen, and cerebellum and to sections from frontal cortex by in vitro autoradiography. In prefrontal cortex from controls, numbers of total beta- and beta 2-adrenoceptors did not significantly correlate with age, but number of beta 1-adrenoceptors showed a weak but significant negative correlation. Binding in tissue particulate preparations to total beta-receptors did not reveal significant differences in samples from prefrontal cortex between AD subjects and age-matched controls. However, beta 1-adrenoceptors were decreased and beta 2-adrenoceptors were increased in number by approximately 30-50% in AD subjects. Thus, the relative ratio of beta 1-/beta 2-receptors was decreased in AD. Binding by in vitro receptor autoradiography performed in a subset of samples of frontal cortex also showed beta 2-adrenoceptors, and less consistently total beta- and beta 1-receptors, to be increased significantly in number in cortical laminae II, III, IV, and V of tissue sections from AD subjects. In these subjects, number of locus ceruleus cells and norepinephrine concentrations in putamen and frontal cortex were markedly reduced compared with values in controls. In the hippocampus, total beta- and both beta 2- and beta 1-adrenoceptors were increased in number in AD. In contrast, in the putamen, where beta 1-receptors predominate, total beta- and beta 1-receptors were significantly decreased in number with no consistent change in content of beta 2-receptors in AD. There were no significant changes in the cerebellum. Specific pindolol binding was not affected by interval between death and sampling of tissue at autopsy. Our results indicate selective changes in number of beta-receptors in AD. These changes in the cortex and hippocampus suggest receptor upregulation in response to noradrenergic deafferentation from the locus ceruleus or may simply reflect glial proliferation in AD.
在阿尔茨海默病(AD)中会出现色素性去甲肾上腺素能蓝斑神经元的丧失,在衰老过程中这种情况出现的程度相对较轻。我们通过125I-吲哚洛尔与前额叶皮质、海马体、壳核和小脑的颗粒膜制剂以及通过体外放射自显影与额叶皮质切片的特异性结合,研究了β-肾上腺素能受体及其亚型β1和β2。在对照组的前额叶皮质中,总的β-和β2-肾上腺素能受体数量与年龄无显著相关性,但β1-肾上腺素能受体数量显示出微弱但显著的负相关。在组织颗粒制剂中,AD患者与年龄匹配的对照组在前额叶皮质样本中与总的β-受体的结合未显示出显著差异。然而,AD患者的β1-肾上腺素能受体数量减少,β2-肾上腺素能受体数量增加约30 - 50%。因此,AD中β1-/β2-受体的相对比例降低。在额叶皮质样本的一个子集中进行的体外受体放射自显影结合也显示,AD患者组织切片的皮质II、III、IV和V层中β2-肾上腺素能受体数量显著增加,总的β-和β1-受体数量增加的情况不太一致。在这些患者中,与对照组相比,蓝斑细胞数量以及壳核和额叶皮质中的去甲肾上腺素浓度显著降低。在海马体中,AD患者总的β-以及β2-和β1-肾上腺素能受体数量均增加。相比之下,在以β1-受体为主的壳核中,AD患者总的β-和β1-受体数量显著减少,β2-受体含量无一致变化。小脑中无显著变化。尸检时,特异性吲哚洛尔结合不受死亡与组织取样间隔时间的影响。我们的结果表明AD中β-受体数量存在选择性变化。皮质和海马体中的这些变化表明,受体上调是对来自蓝斑的去甲肾上腺素能传入缺失的反应,或者可能仅仅反映了AD中的胶质细胞增生。